Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy-Reference-Cited by-同舟云学术

Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy

Published:2022-10 Issue: Volume:173 Page:105835
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Salamone Alessia,Terrone Gaetano,Di Sapia Rossella,Balosso Silvia,Ravizza Teresa,Beltrame Luca,Craparotta Ilaria,Mannarino Laura,Cominesi Sara Raimondi,Rizzi Massimo,Pauletti Alberto,Marchini Sergio,Porcu Luca,Zimmer Till S.,Aronica Eleonora,During Matthew,Abrahams Brett,Kondo Shinichi,Nishi Toshiya,Vezzani Annamaria

Funder

Seventh Framework Programme

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

Neurology

Reference90 articles.

1. Elucidating the potential side effects of current anti-seizure drugs for epilepsy;Akyüz;Curr. Neuropharmacol.,2021

2. Astrocyte immune response in epilepsy;Aronica;Glia,2012

3. Prevalence and incidence of drug-resistant mesial temporal lobe epilepsy in the United States;Asadi-Pooya;World Neurosurg.,2017

4. Current understanding and neurobiology of epileptic encephalopathies;Auvin;Neurobiol. Dis.,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Withaferin A protects against epilepsy by promoting LCN2-mediated astrocyte polarization to stopping neuronal ferroptosis;Phytomedicine;2024-09

2. Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis;Expert Opinion on Drug Discovery;2024-07-29

3. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function;Pharmacology Research & Perspectives;2024-07-11

4. Early treatment with rifaximin during epileptogenesis reverses gut alterations and reduces seizure duration in a mouse model of acquired epilepsy;Brain, Behavior, and Immunity;2024-07

5. Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models;Neuroscience Research;2024-06